Bronchitol® is dry powder mannitol which is inhaled twice daily using a small handheld device. Bronchitol® works by rehydrating the airway/lung surface and promoting a productive cough. Clinical trials have shown that Bronchitol helps to increase mucus clearance, and improve the lung function and the quality of life of people living with cystic fibrosis.
Bronchitol® has already been commercialized in 14 countries. EffRx has an exclusive license agreement with Pharmaxis Ltd, a listed pharmaceutical research company in Australia, for the registration and commercialization of Bronchitol® for cystic fibrosis in Switzerland.
To visit the international Bronchitol website click here